Compare Global X MSCI Argentina ETF (ARGT) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X MSCI Argentina ETF vs Davita Inc — how do they compare? Global X MSCI Argentina ETF trades at $94.69, while Davita Inc trades at $237.66 (market cap $14.94B). The key difference: Davita Inc is trading nearer its 52-week high, Global X MSCI Argentina ETF nearer its low. Which is the better fit depends on your goals.
| ARGT | DVA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $235.71 |
52-Week Low | $67.55 | $103.87 |
Market Cap | — | $14.94B |
Enterprise Value | — | $27.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.
The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.
DaVita (DVA) trades at $232.80, up 1.45% on the day, with a bullish technical signal and strong institutional backing. Recent earnings show mixed quarterly beats, with Q1 2026 exceeding expectations. Revenue growth is steady, reaching $13.64B in 2025, though net income margin dipped to 5.47%. The stock is supported by positive analyst coverage and expansion in kidney care services, including AI-driven scheduling improvements. Current price sits near resistance at $233, with RSI levels indicating potential overbought conditions.
Outlook remains cautiously optimistic given DVA's market leadership and operational improvements, but high debt levels and valuation metrics pose risks. Analyst consensus suggests moderate upside to the $222.80 price target, with 39% buy ratings. Key risks include regulatory changes in healthcare and execution challenges in growth initiatives. The stock's proximity to yearly highs warrants monitoring for pullback opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
